Nkarta Inc (NKTX)

$2.04 +0.08 (4.08%)
Market Cap 147.03M
Revenue (ttm) 0.00
Net Income (ttm) -108.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 964,985
Avg Vol 702,246
Day's Range N/A - N/A
Shares Out 71.03M
Stochastic %K 32%
Beta 0.60
Analysts Strong Sell
Price Target $11.80

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
BiotechValues
BiotechValues Jan. 16 at 6:57 PM
$NKTX at some point this is going to run huge into data in 5 indications. Contrarian play, but that's where money is made. With $317M cash vs. $144M market cap and RA and Tang (activist pot) as top holders, I like my odds for serious upside. The way I see it, with cash into 2029, these guys will either explode up on strong data, or RA and Tang will execute a strategic transaction for the benefit of shareholders. Either way, seems like a no brainer with over $4/share in cash. Cell therapy in AI been hot lately
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 15 at 9:13 PM
$NKTX yeah …Pharma got destroyed today so this was sector related …good time to buy!
0 · Reply
CarOrbitsMars
CarOrbitsMars Jan. 15 at 3:01 PM
$NKTX scarfing this up. Cash to operate for several years and news on the way.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:02 PM
$NKTX RSI: 71.19, MACD: 0.0595 Vol: 0.13, MA20: 1.90, MA50: 1.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 13 at 9:17 PM
$NKTX most stocks are trash at some point …it’s many times all about timing. Right now we look to be at a point of launch for a 20-30% gain…
0 · Reply
canuck_trader92
canuck_trader92 Jan. 13 at 8:35 PM
$NKTX have held for almost 3.5 years. Trash stock that only moves down. Waiting for a miracle on this one
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 13 at 5:27 AM
$NKTX made nice gain so far but expecting much more! 2.25-2.30 coming soon and we’ll see how much volume we can get when we hit that to hopefully go over 2.50 in near future! Let’s see what happens!!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 12 at 4:26 PM
$NKTX buying embarrassing number of shares today at 2.06 🤣
0 · Reply
jerzypawlik
jerzypawlik Jan. 9 at 8:06 PM
$NKTX Keep adding ,and accumulate guys. This will move fast and very soon.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 9 at 10:56 AM
$NKTX been gobbling these up between 2-2.05…..will do again today if possible … From $2–>EXPECT a few increase/decrease movements of up to 15% gains Then a breakout to eventually hit 30-40% gains I expect this to occur in January…possibly February Any catalyst at all or general favorable bio market conditions can get us in the $3’s pretty quickly Let’s see what happens!
0 · Reply
Latest News on NKTX
Nkarta to Participate in Evercore Healthcare Conference

Dec 2, 2025, 7:09 AM EST - 6 weeks ago

Nkarta to Participate in Evercore Healthcare Conference

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nov 22, 2025, 8:28 AM EST - 7 weeks ago

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 10, 2025, 4:01 PM EST - 2 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in November Investor Conferences

Oct 30, 2025, 1:14 PM EDT - 2 months ago

Nkarta to Participate in November Investor Conferences

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Oct 22, 2025, 10:07 AM EDT - 3 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 4 months ago

Nkarta to Participate in a September Investor Conference

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 5 months ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 6 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jul 22, 2025, 12:40 AM EDT - 6 months ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Jun 6, 2025, 8:52 AM EDT - 8 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025, 3:46 PM EDT - 8 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 4:01 PM EDT - 8 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 10 months ago

Nkarta to Participate in an April Investor Conference

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:41 AM EDT - 10 months ago

Nkarta: Grinding Lower, Trying To Find Support

Nkarta: Betting On The Turnaround

Mar 31, 2025, 10:15 AM EDT - 10 months ago

Nkarta: Betting On The Turnaround

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 27, 2025, 12:50 PM EDT - 10 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 10 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

Feb 25, 2025, 8:01 AM EST - 11 months ago

Nkarta to Participate in March Investor Conferences

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta: Finally An Attractive Valuation

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Mar 13, 2024, 1:22 PM EDT - 2 years ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Nkarta: Possible Upside From H1 Update, If Positive

Jan 25, 2024, 12:12 PM EST - 2 years ago

Nkarta: Possible Upside From H1 Update, If Positive

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

BiotechValues
BiotechValues Jan. 16 at 6:57 PM
$NKTX at some point this is going to run huge into data in 5 indications. Contrarian play, but that's where money is made. With $317M cash vs. $144M market cap and RA and Tang (activist pot) as top holders, I like my odds for serious upside. The way I see it, with cash into 2029, these guys will either explode up on strong data, or RA and Tang will execute a strategic transaction for the benefit of shareholders. Either way, seems like a no brainer with over $4/share in cash. Cell therapy in AI been hot lately
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 15 at 9:13 PM
$NKTX yeah …Pharma got destroyed today so this was sector related …good time to buy!
0 · Reply
CarOrbitsMars
CarOrbitsMars Jan. 15 at 3:01 PM
$NKTX scarfing this up. Cash to operate for several years and news on the way.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:02 PM
$NKTX RSI: 71.19, MACD: 0.0595 Vol: 0.13, MA20: 1.90, MA50: 1.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 13 at 9:17 PM
$NKTX most stocks are trash at some point …it’s many times all about timing. Right now we look to be at a point of launch for a 20-30% gain…
0 · Reply
canuck_trader92
canuck_trader92 Jan. 13 at 8:35 PM
$NKTX have held for almost 3.5 years. Trash stock that only moves down. Waiting for a miracle on this one
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 13 at 5:27 AM
$NKTX made nice gain so far but expecting much more! 2.25-2.30 coming soon and we’ll see how much volume we can get when we hit that to hopefully go over 2.50 in near future! Let’s see what happens!!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 12 at 4:26 PM
$NKTX buying embarrassing number of shares today at 2.06 🤣
0 · Reply
jerzypawlik
jerzypawlik Jan. 9 at 8:06 PM
$NKTX Keep adding ,and accumulate guys. This will move fast and very soon.
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jan. 9 at 10:56 AM
$NKTX been gobbling these up between 2-2.05…..will do again today if possible … From $2–>EXPECT a few increase/decrease movements of up to 15% gains Then a breakout to eventually hit 30-40% gains I expect this to occur in January…possibly February Any catalyst at all or general favorable bio market conditions can get us in the $3’s pretty quickly Let’s see what happens!
0 · Reply
jerzypawlik
jerzypawlik Jan. 7 at 9:07 PM
$NKTX Beautiful movement over last few days. Now wr need to break $2.5. It's still undervalued and oversold.
0 · Reply
RetirementByTrade
RetirementByTrade Jan. 7 at 8:54 PM
$PHAT Heyyyyy, whatcha lookin at, $NKTX, $TMCI, $EXAS, $QURE...
0 · Reply
nightstocker15
nightstocker15 Jan. 7 at 5:48 PM
$NKTX nice to see this moving again! Extremely undervalued and has made some big moves in the past. 👀
0 · Reply
Lukey63
Lukey63 Jan. 7 at 2:46 PM
$NKTX There are numerous cheap takeover candidates in biotech, this one being high on my list at a dirt cheap price currently. Low risk high reward. The rumored Lilly acquisition of VTYX (own it) is just an illustration. Granted VTYX is further along and has a very promising anti-inflammatory. But there are plenty of opportunities. I think 2026 is going to see a wave of them.
0 · Reply
elmarklimke
elmarklimke Jan. 1 at 7:15 PM
$NKTX Welcome to the new year! Market analysts have given the company a "Moderate Buy" rating, indicating moderate optimism about future clinical success following significant reorganizations. I'm waiting for the clinical data from Ntrust-1/Ntrust-2 to be released, and then the train will depart at lightning speed.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 1:48 AM
$NKTX RSI: 44.44, MACD: -0.0191 Vol: 0.04, MA20: 1.83, MA50: 1.92 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
jerzypawlik
jerzypawlik Dec. 27 at 2:28 PM
$NKTX Not much time left to buy at this price. It has been manipulated, and accumulated by hedge funds for months now. Don't sell it, keep adding, and next year you'll make tons of money here.
1 · Reply
MarketNarrative
MarketNarrative Dec. 25 at 3:54 PM
$NKTX The setup offers potential, but only if discipline accelerates faster than complexity. Cash flow visibility will determine how patient investors remain. Visible traction across segments would strengthen the thesis. Success from here is primarily about discipline, not discovery.
0 · Reply
01xxxxx
01xxxxx Dec. 24 at 11:07 PM
$NKTX this is only a phase 1 company ? I can see why the stock price is so low
0 · Reply
01xxxxx
01xxxxx Dec. 24 at 10:47 PM
$NKTX Any good reason to get in now ?
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 2:31 PM
$NKTX Share Price: $1.77 Contract Selected: Aug 21, 2026 $2.5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.62 – $0.76 Potential Upside: 53% ROI Time to Expiration: 240 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SharkAttack1
SharkAttack1 Dec. 15 at 3:52 PM
$NKTX Artiva on the move big time, if backed by decent data should see a spill over to this on basis similar MoA and targets
0 · Reply